查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988257

視網膜色素變性市場：按類型、產品和最終用戶分類 - 2026-2032年全球市場預測

Retinitis Pigmentosa Market by Type, Offering, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，視網膜色素變性市場價值將達到 79.6 億美元，到 2026 年將成長至 84.5 億美元，到 2032 年將達到 124 億美元，年複合成長率為 6.53%。

主要市場統計數據
基準年 2025 79.6億美元
預計年份：2026年 84.5億美元
預測年份 2032 124億美元
複合年成長率 (%) 6.53%

視網膜色素變性臨床、診斷和治療趨勢的簡要概述，為相關人員的策略決策提供框架。

視網膜色素變性是一種複雜的疾病，涉及遺傳因素、進行性性視力喪失以及快速發展的臨床和技術應對措施。在分子遺傳學、視網膜成像和治療設備進步的推動下，目前的情況正從單純的臨床觀察轉向精準診斷和標靶干預。相關人員現在需要一份簡潔、循證的分析報告，整合診斷路徑、治療方法和醫療服務，以幫助制定研發和商業化策略。

評估 2025 年美國預期關稅調整對眼科治療供應鏈韌性、籌資策略和全球臨床試驗物流的影響。

美國預計2025年的關稅調整和貿易政策變化將對視網膜色素變性生態系統產生多方面影響，尤其對跨境零件和技術而言。專用影像設備、基因治療生產中使用的生物活性材料以及植入式醫療設備零件的進口成本上升，可能會影響醫院、診斷中心和眼科專科醫療機構的籌資策略。為此，製造商和臨床服務提供者正在評估供應鏈韌性、本地採購和生產本地化等措施，以降低成本風險並確保關鍵診斷和治療工具的可靠供應。

將遺傳亞型、診斷方法、治療途徑和醫療保健服務環境與策略發展和實施考慮因素聯繫起來的詳細細分分析。

了解視網膜色素變性的分型對於協調臨床開發和商業策略至關重要。區分體染色體顯性遺傳、體染色體隱性遺傳和X連鎖視網膜色素變性對於制定基於類型的研究和策略至關重要，因為每種遺傳結構都會導致不同的遺傳模式、自然病程和潛在的靶向分子機制。這些差異指導介入通訊協定的合格標準，影響臨床諮詢方法，並決定特定基因療法的適用性。

從區域比較觀點看美洲、歐洲、中東和非洲以及亞太地區的臨床引進、監管差異和能力建構挑戰。

區域趨勢正在影響視網膜色素變性創新診斷和治療技術的推廣，並推動這些技術走向不同的應用路徑。在美洲，臨床研究基礎設施和專科醫療中心的集中分佈，使得臨床實驗參與者能夠快速招募，並能儘早應用先進的影像診斷和介入措施。然而，這也需要與保險公司密切合作，並建立以長期療效為導向的證據。在該地區，從成功的臨床試驗到常規臨床實踐的轉化，往往取決於能否透過真實世界數據證明其價值，並使其與永續的報銷機制相契合。

企業策略行動和夥伴關係模式塑造了在治療方法研發、生產規模化以及綜合診斷和治療解決方案方面的領導地位。

產業相關人員正從各自為政的技術孤島轉變為整合診斷、治療和遞送平台的協作生態系統。基因治療公司擴大與專業的合約研發生產機構（CDMO）合作，以應對載體生產的挑戰和規模化生產的複雜性。專注於視網膜植入的醫療設備公司正在投資材料科學、感測器介面和手術遞送系統，同時尋求與臨床中心合作，以在真實臨床環境中檢驗療效。

透過整合診斷準確性、供應鏈彈性、監管合規性和分階段商業化，提供加速部署的實用策略指導。

產業領導者應優先考慮制定整合策略，同時兼顧診斷準確性、治療永續性和可操作的交付模式。首先，將臨床開發與先進的診斷能力結合，可以提高患者篩選的準確性和終點指標的敏感度。投資於標準化的視網膜電圖通訊協定、高解析度光學同調斷層掃描(OCT) 成像和集中式影像分析，可以提高臨床試驗和上市後監測的效率。其次，透過區域製造夥伴關係和採購來源多元化，建立具有韌性的供應鏈，可以降低貿易中斷和關稅波動帶來的風險，從而確保臨床項目的可及性和連續性。

我們採用透明的混合方法研究途徑，結合專家訪談、文獻分析和資料三角驗證，為研究結果提供了實用可靠的見解。

本研究方法結合了跨學科證據整合、專家諮詢和方法三角驗證，以獲得可靠且可操作的見解。主要資料來源是對臨床醫生、臨床實驗研究員、生產專家和監管顧問進行的結構化訪談，旨在收集關於診斷方法引入、治療方法研發挑戰和物流實施的第一手觀點。輔助研究包括查閱同行評審文獻、監管指導文件和公開的臨床試驗註冊資訊，以便將研究結果置於當代科學和政策框架中進行解讀。

將臨床和營運需求結合，使診斷進步和治療創新保持一致，從而在患者和系統層面產生持久的影響。

視網膜色素變性正處於一個轉折點，診斷的明確和治療的創新正在融合，從而實現日益個性化的治療路徑。識別基因亞型、先進的影像學和電生理檢測，以及與多種治療方法的相互作用，都為改變疾病進程和改善患者預後創造了機會。然而，要實現這一潛力，需要協調投資於實證醫學證據的產生、生產基礎設施的建設，以及與保險公司的合作，以確保治療方法能夠從臨床試驗階段過渡到持續的臨床應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 視網膜色素變性市場：依類型分類

  • 體染色體顯性遺傳性視網膜色素變性
  • 體染色體隱性遺傳性視網膜色素變性
  • X連鎖視網膜色素變性

第9章 視網膜色素變性市場：依產品/服務分類

  • 診斷
    • 視網膜電圖
    • 眼底照片
    • 光學同調斷層掃描
  • 治療
    • 基因治療
    • 視網膜植入
    • 幹細胞療法

第10章 視網膜色素變性市場：依最終用戶分類

  • 診斷中心
  • 醫院和診所
  • 專科眼科診所

第11章 視網膜色素變性市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 視網膜色素變性市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 視網膜色素變性市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國視網膜色素變性市場

第15章：中國視網膜色素變性市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 4D Molecular Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Axovia Therapeutics
  • Beacon Therapeutics Limited
  • BIOGEN INC.
  • Clino Corporation
  • Editas Medicine, Inc.
  • GENSIGHT BIOLOGICS
  • Horama SA
  • jCyte, Inc.
  • Johnson & Johnson Services, Inc.
  • Kiora Pharmaceuticals, Inc.
  • MeiraGTx Holdings PLC
  • Mimetogen Pharmaceuticals
  • Nacuity Pharmaceuticals
  • Nanoscope Therapeutics, Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Oxford Biomedica PLC
  • Precision BioSciences, Inc.
  • ProQR Therapeutics NV
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd.
  • Skyline Therapeutics
  • Spark Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • ViGeneron GmbH
Product Code: MRR-7A1CEDCFE674

The Retinitis Pigmentosa Market was valued at USD 7.96 billion in 2025 and is projected to grow to USD 8.45 billion in 2026, with a CAGR of 6.53%, reaching USD 12.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.96 billion
Estimated Year [2026] USD 8.45 billion
Forecast Year [2032] USD 12.40 billion
CAGR (%) 6.53%

Concise orientation to the evolving clinical, diagnostic, and therapeutic landscape of retinitis pigmentosa that frames strategic decision-making for stakeholders

Retinitis pigmentosa presents a complex intersection of genetics, progressive vision loss, and rapidly evolving clinical and technological responses. The landscape has shifted from descriptive clinical observation to precision diagnostics and targeted interventions, driven by advances in molecular genetics, retinal imaging, and interventional devices. Stakeholders now require concise, clinically grounded analysis that synthesizes diagnostic pathways, therapeutic modalities, and care delivery settings to inform development and commercialization strategies.

This executive summary grounds readers in core clinical characteristics and emerging modalities without presuming prior familiarity with specialized subtypes. It emphasizes translational trends from bench to bedside and highlights how diagnostic resolution-ranging from functional assessments to high-resolution structural imaging-now underpins eligibility for novel therapeutics. By connecting diagnostic sophistication with treatment innovations, the introduction sets the stage for deeper analysis of competitive dynamics, regulatory pressures, and operational considerations that follow.

The retinitis pigmentosa landscape is undergoing transformative shifts driven by converging advances in genetics, imaging, and therapeutic engineering. Gene-based approaches have moved from conceptual phases into clinical assessment, reshaping expectations for durable disease modification. Concurrently, improvements in retinal imaging-especially spectral-domain and swept-source optical coherence tomography and fundus-level modalities-have increased the granularity with which clinicians track progression and stratify patients for trials. These diagnostic enhancements, when combined with standardized functional tests such as electroretinography, create more precise eligibility criteria and accelerate adaptive trial designs.

In parallel, device innovation in retinal implantation and prosthetic interfaces has broadened therapeutic options for patients with advanced photoreceptor loss, while stem cell approaches pursue regenerative pathways with distinct safety and manufacturing profiles. Transitional regulatory frameworks and payer conversations now reflect an understanding that long-term real-world outcomes and quality-of-life metrics will shape adoption. Furthermore, digital health integrations and AI-enabled analysis are enhancing triage and monitoring, enabling decentralized care models that can identify candidates earlier and reduce diagnostic latency. Taken together, these shifts are creating a more integrated ecosystem where diagnostics, therapeutics, and care delivery co-evolve toward patient-centered, evidence-driven pathways.

Assessment of how anticipated 2025 United States tariff adjustments influence supply chain resilience, procurement strategies, and global clinical trial logistics for ocular therapeutics

Anticipated tariff changes and trade policy adjustments in the United States for 2025 have multifaceted implications for the retinitis pigmentosa ecosystem, particularly for components and technologies that cross borders. Increased import costs for specialized imaging equipment, bioactive materials used in gene therapy manufacturing, and implantable device components can affect procurement strategies for hospitals, diagnostic centers, and specialty eye care facilities. In response, manufacturers and clinical providers are evaluating supply chain resilience, regional sourcing, and production localization to mitigate cost exposure and maintain predictable access to critical diagnostic and therapeutic tools.

Beyond raw costs, tariffs influence strategic decisions about where to site manufacturing and final assembly for gene vectors, cell therapy products, and implantable devices. They can also affect the cadence and design of multicenter clinical trials when investigational products and ancillary devices move between sites. Stakeholders increasingly incorporate trade policy scenarios into regulatory planning and contracting with subcontractors. As a result, clinicians and administrators are placing more emphasis on early engagement with suppliers and diversified vendor relationships to preserve continuity of care and trial enrollment despite changing trade dynamics.

In-depth segmentation analysis linking genetic subtypes, diagnostic modalities, therapeutic pathways, and care settings to strategic development and adoption considerations

Understanding segmentation is central to aligning clinical development and commercial strategies in retinitis pigmentosa. When studies and strategies are informed by Type, differentiation among autosomal dominant retinitis pigmentosa, autosomal recessive retinitis pigmentosa, and X-linked retinitis pigmentosa is essential because each genetic architecture yields different inheritance patterns, natural history considerations, and targetable molecular mechanisms. These distinctions guide eligibility criteria for interventional protocols, influence counseling approaches in clinical practice, and determine the applicability of specific gene-based modalities.

Similarly, segmentation based on Offering clarifies where investments and operational resources should be allocated. Diagnosis and Treatment represent two complementary pillars of care. Under Diagnosis, electroretinography offers functional assessment of retinal response, fundus photography provides wide-field structural context, and optical coherence tomography supplies high-resolution cross-sectional views; together they form a diagnostic toolkit that supports stratification and monitoring. Under Treatment, gene therapy pursues corrective or augmentative approaches at the molecular level, retinal implantation seeks to restore visual input through engineered prostheses, and stem cell therapy aims to replace or rescue degenerating cells-each pathway presents distinct regulatory, manufacturing, and long-term evidence considerations.

End-User segmentation further informs distribution and adoption strategy across care settings. Diagnostic centers, hospitals and clinics, and specialty eye care centers each play unique roles in patient identification, procedural delivery, and longitudinal follow-up. Diagnostic centers often lead in access to high-throughput imaging and electrophysiology, hospitals and clinics integrate multidisciplinary care and interventional procedures, and specialty eye care centers provide concentrated expertise for advanced therapies and long-term patient management. Aligning product development, education, and reimbursement engagement with these end-user profiles enhances the likelihood of successful adoption and sustained clinical impact.

Comparative regional perspective on clinical adoption, regulatory variation, and capacity-building imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape the diffusion of diagnostic and therapeutic innovations for retinitis pigmentosa and drive differentiated pathways to adoption. In the Americas, clinical research infrastructures and a high concentration of specialty care centers enable rapid trial recruitment and early uptake of advanced imaging and interventional procedures, but they also necessitate robust payer engagement and evidence generation focused on long-term outcomes. Transitioning from trial success to routine care in this region often hinges on demonstrating value through real-world data and aligning with durable reimbursement frameworks.

In Europe, Middle East & Africa, heterogeneous regulatory landscapes and variable healthcare funding models create both challenges and opportunities. High-income jurisdictions within this region often prioritize early access schemes and conditional approvals that can accelerate patient access to innovative therapies, while emerging markets may adopt different pathways emphasizing cost-effectiveness and technology transfer. Building regional partnerships with academic centers and leveraging pan-regional regulatory harmonization efforts can streamline multi-country development strategies.

In the Asia-Pacific region, expanding clinical capabilities, growing investment in biotechnology, and rising adoption of digital health tools are accelerating participation in global research efforts. Local manufacturing initiatives and public-private collaborations can facilitate supply chain diversification and reduce lead times for complex biologics and devices. Consequently, strategies that account for regional regulatory idiosyncrasies, capacity-building partnerships, and phased market entry tend to be more resilient and effective across this diverse set of jurisdictions.

Strategic corporate behaviors and partnership models shaping leadership in therapeutic development, manufacturing scale-up, and integrated diagnostic-therapeutic solutions

Industry participants are evolving from discrete technology silos toward collaborative ecosystems that integrate diagnostics, therapeutics, and delivery platforms. Companies working on gene therapies are increasingly partnering with specialized contract development and manufacturing organizations to address vector production challenges and scale-up complexities. Device-oriented firms focused on retinal implantation are investing in materials science, sensor interfaces, and surgical delivery systems while exploring partnerships with clinical centers to validate outcomes in real-world settings.

Across players pursuing regenerative approaches such as stem cell therapies, there is a growing emphasis on standardized manufacturing protocols, potency assays, and long-term safety monitoring. These priorities drive strategic alliances between clinical research institutions, contract manufacturers, and regulatory consultants to ensure that translational pipelines are robust. Moreover, competitive differentiation frequently emerges from intellectual property around delivery mechanisms, cryopreservation methods, and patient selection algorithms rather than solely from candidate biology. Companies that combine strong clinical evidence generation with scalable manufacturing and clear commercialization pathways position themselves to lead in the evolving landscape.

Action-oriented strategic guidance for integrating diagnostic precision, supply chain resilience, regulatory alignment, and phased commercialization to accelerate adoption

Industry leaders should prioritize integrated strategies that simultaneously address diagnostic precision, therapeutic durability, and practical delivery models. First, aligning clinical development with advanced diagnostic capabilities will improve patient selection and endpoint sensitivity; investments in standardized electroretinography protocols, high-resolution optical coherence tomography imaging, and centralized image analysis can enhance trial efficiency and post-market surveillance. Second, establishing resilient supply chains through regional manufacturing partnerships and diversified sourcing mitigates risks associated with trade disruptions and tariff variability, thereby preserving access and continuity for clinical programs.

Third, engaging early with regulators and payers to define clinically meaningful endpoints and acceptable real-world evidence pathways will accelerate reimbursement discussions and market access. Fourth, adopt a phased commercialization approach that leverages specialty eye care centers for early adoption while building referral networks from diagnostic centers and hospitals to support broader access. Fifth, invest in patient engagement and long-term outcome tracking to demonstrate quality-of-life benefits and to support value-based contracting. By executing against these interlocking recommendations, organizations can translate scientific advances into scalable therapies that reach patients efficiently and sustainably.

Transparent mixed-methods research approach integrating expert interviews, literature synthesis, and data triangulation to underpin practical and reliable insights

The research approach combined multidisciplinary evidence synthesis, expert consultation, and methodological triangulation to develop robust, actionable insights. Primary inputs included structured interviews with clinicians, trial investigators, manufacturing specialists, and regulatory advisors to capture firsthand perspectives on diagnostic adoption, therapeutic development challenges, and deployment logistics. Secondary research comprised a review of peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial registries to contextualize findings within contemporary scientific and policy frameworks.

Data synthesis employed cross-validation techniques to reconcile differing stakeholder perspectives and to identify consistent patterns across evidence streams. Sensitivity checks and methodological audits were applied to ensure that conclusions reflect replicable trends rather than isolated case examples. Limitations of the approach include reliance on available published evidence and stakeholder availability for interviews; where gaps existed, findings were framed conservatively and presented with clear assumptions. Overall, this mixed-methods design supports confident, pragmatic recommendations while transparently acknowledging areas where additional primary data would strengthen specific conclusions.

Synthesis of clinical and operational imperatives that must align to translate diagnostic advances and therapeutic innovation into sustained patient and system-level impact

Retinitis pigmentosa stands at an inflection point where diagnostic clarity and therapeutic innovation converge to enable increasingly personalized care pathways. The interplay between genetic subtype characterization, enhanced imaging and electrophysiology, and multiple therapeutic modalities creates opportunities to alter disease course and improve patient outcomes. However, realizing that potential requires coordinated investment in evidence generation, manufacturing infrastructure, and payer engagement to ensure therapies move from trials into sustained clinical use.

Strategically, stakeholders who prioritize diagnostic integration, supply chain resilience, and early regulatory and payer dialogue will be better positioned to translate scientific advances into durable patient benefit. Continued collaboration across academic centers, clinical sites, industry partners, and policy actors will be essential to standardize outcome measures, optimize patient access, and build the long-term datasets that justify broader adoption. In sum, the field is poised for meaningful progress provided that operational and evidence-generation challenges are addressed in parallel with scientific development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Retinitis Pigmentosa Market, by Type

  • 8.1. Autosomal Dominant Retinitis Pigmentosa
  • 8.2. Autosomal Recessive Retinitis Pigmentosa
  • 8.3. X-linked Retinitis Pigmentosa

9. Retinitis Pigmentosa Market, by Offering

  • 9.1. Diagnosis
    • 9.1.1. Electroretinography
    • 9.1.2. Fundus Photography
    • 9.1.3. Optical Coherence Tomography
  • 9.2. Treatment
    • 9.2.1. Gene Therapy
    • 9.2.2. Retinal Implantation
    • 9.2.3. Stem Cell Therapy

10. Retinitis Pigmentosa Market, by End-User

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals & Clinics
  • 10.3. Specialty Eye Care Centers

11. Retinitis Pigmentosa Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Retinitis Pigmentosa Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Retinitis Pigmentosa Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Retinitis Pigmentosa Market

15. China Retinitis Pigmentosa Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. 4D Molecular Therapeutics, Inc.
  • 16.6. Astellas Pharma Inc.
  • 16.7. Axovia Therapeutics
  • 16.8. Beacon Therapeutics Limited
  • 16.9. BIOGEN INC.
  • 16.10. Clino Corporation
  • 16.11. Editas Medicine, Inc.
  • 16.12. GENSIGHT BIOLOGICS
  • 16.13. Horama SA
  • 16.14. jCyte, Inc.
  • 16.15. Johnson & Johnson Services, Inc.
  • 16.16. Kiora Pharmaceuticals, Inc.
  • 16.17. MeiraGTx Holdings PLC
  • 16.18. Mimetogen Pharmaceuticals
  • 16.19. Nacuity Pharmaceuticals
  • 16.20. Nanoscope Therapeutics, Inc.
  • 16.21. Novartis AG
  • 16.22. Ocugen, Inc.
  • 16.23. Oxford Biomedica PLC
  • 16.24. Precision BioSciences, Inc.
  • 16.25. ProQR Therapeutics N.V.
  • 16.26. Sanofi S.A.
  • 16.27. Santen Pharmaceutical Co., Ltd.
  • 16.28. Skyline Therapeutics
  • 16.29. Spark Therapeutics, Inc.
  • 16.30. Sun Pharmaceutical Industries Ltd.
  • 16.31. Takeda Pharmaceutical Company Limited
  • 16.32. ViGeneron GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY ELECTRORETINOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY ELECTRORETINOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY ELECTRORETINOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY FUNDUS PHOTOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY FUNDUS PHOTOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY FUNDUS PHOTOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY RETINAL IMPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY RETINAL IMPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY RETINAL IMPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY EYE CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY EYE CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY EYE CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 108. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 110. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 126. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 127. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 128. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 132. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 133. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 134. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)